Protagonist Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTGX and other ETFs, options, and stocks.About PTGX
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943.
CEODinesh V. Patel
CEODinesh V. Patel
Employees126
Employees126
HeadquartersNewark, California
HeadquartersNewark, California
Founded2006
Founded2006
Employees126
Employees126
PTGX Key Statistics
Market cap3.63B
Market cap3.63B
Price-Earnings ratio82.60
Price-Earnings ratio82.60
Dividend yield—
Dividend yield—
Average volume1.16M
Average volume1.16M
High today$59.64
High today$59.64
Low today$57.95
Low today$57.95
Open price$59.07
Open price$59.07
Volume890.37K
Volume890.37K
52 Week high$61.89
52 Week high$61.89
52 Week low$33.31
52 Week low$33.31
PTGX News
TipRanks 4d
Protagonist Therapeutics: Buy Rating Backed by Promising Drug Assets and Strategic PartnershipsProtagonist Therapeutics (PTGX) has received a new Buy rating, initiated by Leerink Partners analyst, Faisal Khurshid. Elevate Your Investing Strategy: Take adv...
Analyst ratings
92%
of 13 ratingsBuy
92.3%
Hold
7.7%
Sell
0%
People also own
Based on the portfolios of people who own PTGX. This list is generated using Robinhood data, and it’s not a recommendation.